PpProf. Peptide
Back to Peptide Library

Sermorelin + Ipamorelin

Growth HormoneResearch-GradeCombination Blend

Last reviewed: May 28, 2026

Also Known As: Sermorelin / Ipamorelin Stack, Serm + Ipa Blend, Beginner GH Stack

Peptide Class: Growth Hormone Secretagogue Blend (2-component)

Regulatory Status: Sermorelin available via compounding pharmacy (Rx); Ipamorelin research-grade only; combination research-grade only

What is Sermorelin + Ipamorelin?

Sermorelin + Ipamorelin is a 2-component growth hormone secretagogue blend combining Sermorelin (a GHRH 1-29 analog, ~10–20 min half-life) and Ipamorelin (a selective GHS-R1a / ghrelin receptor agonist, ~2 h half-life). Like the GH Stack (CJC-1295 + Ipamorelin), it activates both the GHRH receptor and the ghrelin receptor on pituitary somatotrophs simultaneously, producing supra-additive growth hormone release (2–4× greater than either compound alone) in a pulsatile pattern that mirrors physiological GH secretion. What distinguishes this stack is its regulatory footing: Sermorelin was FDA-approved as Geref for pediatric GH deficiency and is available via compounding pharmacies for adult GH deficiency — giving it the strongest safety and regulatory pedigree of the GHRH analogs. Both components are short-acting, preserving physiological pulsatile GH release, and both are WADA S2 prohibited.

This is the recommended starting point on the GH secretagogue stack progression: Sermorelin + Ipamorelin → GH Stack (CJC-1295 no-DAC + Ipamorelin) → CJC-1295 DAC + Ipamorelin (once-weekly convenience, non-pulsatile).

New to peptide research? Start with the basics →

Reported benefits:

  • Synergistic GH amplification beyond individual compound effects (2–4× greater AUC vs monotherapy)
  • Physiologically pulsatile GH release pattern (both components short-acting — preserves natural feedback regulation)
  • Elevated IGF-1 supporting anabolic, metabolic, and tissue-repair processes
  • No significant cortisol, ACTH, or prolactin elevation (Ipamorelin's selectivity advantage vs older GHRPs)
  • Enhanced slow-wave sleep through GH-mediated nocturnal GH pulse reinforcement
  • Strongest regulatory footing of any GHRH+GHRP stack — Sermorelin's compounding-pharmacy approval provides real-world clinical exposure data

Common research dose: Sermorelin 100–300 mcg + Ipamorelin 200–300 mcg subcutaneously, pre-bed on an empty stomach, once daily (optional second dose post-workout). Titrate up from lower doses over weeks 1–2.

Where to buy: Typically sold as separate vials; some vendors offer a pre-blended Sermorelin + Ipamorelin vial. Neither component is FDA-approved at research-grade doses. See Verified Discount Codes → for current options.

How does Sermorelin + Ipamorelin work?

Sermorelin + Ipamorelin combines two peptides that hit the same pituitary gland through different receptor doors. Sermorelin is a GHRH 1-29 analog — it activates the GHRH receptor on pituitary somatotrophs, the same receptor the body's natural growth hormone-releasing hormone uses. Ipamorelin is a selective GHRP, activating the ghrelin / GHS-R1a receptor on the same cells. When both receptors fire simultaneously, the pituitary releases more GH than either signal triggers alone — in a pulsatile pattern that mirrors physiological GH secretion.

  1. Sermorelin — GHRH Pathway Activation [1][4]. Sermorelin (GHRH 1-29) binds the GHRH receptor on anterior pituitary somatotrophs. Activation triggers a Gs-coupled cAMP/PKA cascade that drives GH gene transcription and primes the somatotroph for GH release. Half-life is approximately 10–20 minutes — even shorter than CJC-1295 without DAC (~30 min) — making it the most rapidly cleared of the GHRH analogs and the one that most tightly preserves discrete, pulsatile GH release.
  2. Ipamorelin — GHS-R1a Pathway Activation [1][2]. Ipamorelin selectively activates the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor) on the same pituitary somatotrophs. Activation triggers a Gq-coupled phospholipase C / IP3 / calcium / PKC cascade that drives immediate GH release. Ipamorelin's half-life is approximately 2 hours. Its defining feature is selectivity: GH pulse without meaningful cortisol, ACTH, prolactin, FSH, LH, or TSH elevation — distinguishing it from older GHRPs.
  3. Dual-Pathway Synergy [2]. Simultaneous GHRHR activation (cAMP/PKA cascade from Sermorelin) and GHS-R1a activation (calcium/PKC cascade from Ipamorelin) converge at the somatotroph secretory machinery. The two second-messenger cascades amplify each other — co-administration produces 2–4× greater GH area under the curve than either compound alone. This supra-additive synergy is the core rationale for combining a GHRH analog with a GHRP.
  4. Physiological Pulsatility [3]. The short half-lives of both Sermorelin (~10–20 min) and Ipamorelin (~2 h) produce a discrete GH pulse over 1–2 hours, then return to baseline. This mirrors the body's natural overnight and post-exercise GH pulses, preserving feedback regulation (somatostatin inhibition, IGF-1 feedback) and avoiding the sustained, non-pulsatile GH elevation produced by DAC-conjugated analogs or exogenous HGH. Pulsatile GH is how the pituitary naturally operates.
  5. Downstream IGF-1 Elevation [3]. The amplified pituitary GH output drives elevated hepatic IGF-1 production. IGF-1 carries most of the systemic anabolic and tissue-repair effects — lean mass support, recovery enhancement, joint and connective tissue benefit. Both Sermorelin and CJC-1295 (no-DAC) drive measurable IGF-1 elevation within days of starting a stack protocol.

What is Sermorelin + Ipamorelin used for?

The Sermorelin + Ipamorelin stack is used for the same GH-axis research applications as the GH Stack (CJC-1295 + Ipamorelin), with the additional context that Sermorelin's clinical history provides a closer regulatory analog for safety class. Researchers use it for body composition, recovery, sleep quality, and GH-axis support in the context of age-related GH decline.

  1. Sleep Quality [5]. GHRH administration (including Sermorelin analogs) enhances slow-wave sleep and reinforces the natural nocturnal GH pulse. Pre-bed dosing of Sermorelin + Ipamorelin is studied for sleep-quality improvement. Subjective sleep improvements are among the first effects reported, often within 1–2 weeks.
  2. Body Composition [3]. Elevated GH and downstream IGF-1 support lean muscle synthesis, visceral fat metabolism, and overall body composition. The most-cited GH secretagogue use case in the research and biohacking communities. Effects accumulate over 12–24 weeks of active research protocol.
  3. Recovery and Tissue Repair. Elevated GH and IGF-1 support faster recovery from exercise-induced muscle damage through enhanced protein synthesis and cellular repair mechanisms. Often stacked with BPC-157 and TB-500 for combined local + systemic tissue-repair coverage.
  4. GH-Axis Support in Aging [4]. GH axis activity declines significantly with age. Sermorelin has compounding-pharmacy approval for adult GH deficiency — providing the closest clinical analog for GH secretagogue use in this context. The stack is researched as a means of supporting GH axis function to counteract age-related muscle loss, fat accumulation, and metabolic decline.
  5. Joint and Connective Tissue Support. IGF-1 supports collagen synthesis and connective tissue maintenance. Common research application alongside resistance training and tissue-repair peptide stacks.

How long does Sermorelin + Ipamorelin take to work?

Effects build over weeks. Sleep quality and subjective recovery improvements often appear within the first 1–2 weeks. Subjective joint, connective-tissue, and recovery effects accumulate over 4–8 weeks. Body composition changes take 12–24 weeks to become measurable.

IGF-1 elevation is detectable in serum within days of starting the stack. The Sermorelin + Ipamorelin combination does not produce dramatic short-term changes — it produces gradual, accumulating effects driven by sustained pulsatile elevation of endogenous GH and downstream IGF-1. Standard research cycles run 8–16 weeks active with a similar off-period to avoid pituitary receptor desensitization. Sermorelin's clinical data in GH deficiency shows continued benefit through multi-month treatment with appropriate cycling.

How is Sermorelin + Ipamorelin dosed?

Sermorelin + Ipamorelin is administered as a subcutaneous injection. Both components are short-acting, so daily (or twice-daily) dosing is required. The protocol below is derived from each compound's individual research literature and community use — there is no controlled trial of the combination as a single product.

Standard research protocol:

  1. Sermorelin dose. 100–300 mcg subcutaneously per injection.
  2. Ipamorelin dose. 200–300 mcg subcutaneously per injection (same injection or separate syringe).
  3. Frequency. Once daily (pre-bed preferred) or twice daily (pre-bed + post-workout). Pre-bed is the recommended starting point for new researchers.
  4. Timing. Empty stomach, at least 2 hours after the last meal. Elevated insulin and somatostatin blunt the GH response — this is the most important timing constraint.
  5. Titration. Start at the lower end (Sermorelin 100 mcg + Ipamorelin 200 mcg once daily pre-bed) for weeks 1–2, then increase by ~50 mcg each peptide every 1–2 weeks as tolerated toward target doses.
  6. Cycle. 8–12 weeks active, 4-week minimum off-period before re-cycling.

Vial formats and reconstitution math

Common SKUs. Sermorelin is typically sold in 2 mg or 5 mg lyophilized vials; Ipamorelin in 2 mg or 5 mg lyophilized vials. Some vendors offer a pre-blended Sermorelin + Ipamorelin vial (e.g., 5 mg total: 2 mg Sermorelin + 3 mg Ipamorelin, or equal-weight formulations). Check the vendor's label carefully for component weights.

Reconstitution. Use bacteriostatic water for injection (BAC water). A standard approach: add 2 mL BAC water to a 2 mg Sermorelin vial (1 mg/mL = 1,000 mcg/mL), giving 10 units per 100 mcg dose on a U-100 insulin syringe. Add 2 mL BAC water to a 2 mg Ipamorelin vial (1 mg/mL), giving 20 units per 200 mcg dose. Swirl gently — do not shake — to avoid damaging the peptides.

Separate vials vs pre-blend. Most researchers buy Sermorelin and Ipamorelin as separate vials — this lets them adjust each peptide's dose independently and stagger titration. A pre-blended vial locks the ratio, which is acceptable if that ratio matches the target protocol.

BAC waterConc. (2 mg vial)100 mcg dose150 mcg dose200 mcg dose300 mcg dose
1 mL2 mg/mL (2,000 mcg/mL)5 units7.5 units10 units15 units
2 mL1 mg/mL (1,000 mcg/mL)10 units15 units20 units30 units

Table above applies to a 2 mg single-peptide vial. For different vial sizes or pre-blended vials, use the dosage calculator for ratio-specific math.

Sermorelin + Ipamorelin is not FDA-approved as a research blend. Dosing is derived from each component's individual literature plus research-community protocols — there are no approved retail dosing standards for the combination.

Need to calculate your dose? Convert mg to syringe units and plan reconstitution with the dosage calculator →.

How is Sermorelin + Ipamorelin administered?

Both peptides are administered by subcutaneous injection using a small insulin syringe. Pre-bed dosing on an empty stomach is the canonical protocol because it synchronizes with the body's natural overnight GH pulse and the sleep-stage-dependent GH secretion pattern.

  1. Route. Subcutaneous injection. Common sites are the abdomen (avoiding a 2-inch radius around the navel), upper outer thighs, and back of the upper arms.
  2. Time of day. Pre-bed is the default — 30–60 minutes before sleep on an empty stomach. An optional second dose may be added post-workout if running a 2× daily protocol.
  3. Empty stomach. At least 2 hours after the last meal. Elevated insulin and somatostatin blunt the GH response — this is the most important timing rule for this stack.
  4. Same injection or separate syringes. If using separate vials, both peptides may be drawn into the same insulin syringe for a single injection, or administered as separate injections at the same site-rotation point. Do not mix in the same vial storage.
  5. Site rotation. Alternate injection sites each dose. Stay at least 1 inch from previous injection sites to minimize injection-site reactions.
  6. Reconstitution. Use bacteriostatic water for injection (BAC water). Swirl gently — do not shake — to avoid damaging the lyophilized peptides.
  7. Missed dose. Resume on the next scheduled dose. Do not double-dose. For once-daily protocols, a single missed night has minimal impact; consistency over weeks matters more than any single injection.
  8. Cycling. 8–12 weeks on, 4-week minimum off. Cycling avoids pituitary receptor desensitization and preserves GH-axis responsiveness over repeated research cycles.

Timing context. Unlike once-weekly GLP-class peptides, Sermorelin and Ipamorelin are both short-acting and timing-sensitive: insulin and somatostatin from a recent meal will blunt the GH response. The table below summarizes the timing variables that most affect the stack's GH output.

AspectRecommendation
Frequency1–2× daily (pre-bed primary; post-workout optional 2nd dose)
Best time of dayPre-bed, 30–60 min before sleep — aligns with natural nocturnal GH pulse and slow-wave sleep onset
FoodEmpty stomach, 2+ hours after last meal (insulin + somatostatin blunt GH response)
Injection site rotationAbdomen (avoid 2-inch radius around navel), upper outer thighs, back of upper arms — alternate per injection
Half-livesSermorelin ~10–20 min; Ipamorelin ~2 h — both short-acting, daily or twice-daily dosing required
Steady-state timelineSleep quality 1–2 weeks; recovery 4–8 weeks; body composition 12–24 weeks

What does Sermorelin + Ipamorelin stack well with?

The stack pairs well with tissue-repair peptides and metabolic compounds — GH-mediated systemic IGF-1 elevation amplifies the local effects of other interventions. Avoid double-dosing the GH axis by adding another GH secretagogue (MK-677, CJC-1295) or running standalone Sermorelin or Ipamorelin protocols on top of this combination.

  1. Tissue-repair peptides. The most common pairing. BPC-157 + TB-500 (or the Wolverine Stack) for combined local + systemic tissue repair. Elevated IGF-1 amplifies the substrate for local healing peptides.
  2. Stepping up to the GH Stack. Researchers who have established tolerability with Sermorelin + Ipamorelin and want slightly longer GHRH action per dose can step up to GH Stack (CJC-1295 no-DAC + Ipamorelin). The CJC-1295 no-DAC half-life of ~30 min allows slightly longer pituitary priming per injection versus Sermorelin's ~10–20 min.
  3. Metabolic / weight peptides. GH-axis activation provides lean-mass preservation during caloric restriction — Sermorelin + Ipamorelin is sometimes run alongside fat-loss protocols. Elevated IGF-1 helps offset catabolism.
  4. Tesamorelin substitution. Tesamorelin (FDA-approved GHRH analog for HIV-associated lipodystrophy) is the other regulatory-clean GHRH analog. Researchers targeting visceral fat specifically sometimes substitute Tesamorelin for Sermorelin in this stack format.
  5. Resistance training + adequate protein. Required for GH-mediated anabolic effect. GH and IGF-1 elevation without mechanical loading and protein substrate produces less lean-mass benefit. Recommended: 1.2–1.6 g protein/kg body weight throughout the research cycle.
  6. Avoid: MK-677. MK-677 (ibutamoren) is another GH secretagogue (ghrelin receptor agonist) — stacking with Ipamorelin doubles the GHS-R1a activation without proportional benefit and increases appetite and potential cortisol side effects.
  7. Avoid: full-dose standalone CJC-1295 or Sermorelin. Adding a standalone CJC-1295 or Sermorelin protocol on top of this stack doubles the GHRH-pathway activation without independent benefit. Choose one GHRH analog per protocol.

What are the side effects of Sermorelin + Ipamorelin?

Most reported side effects are mild and reflect GH-axis physiology — water retention, transient flushing, injection-site reactions, and early sleep changes. Ipamorelin's selectivity keeps the profile cleaner than older GHRP stacks. Theoretical long-term concerns are insulin resistance and receptor desensitization from sustained GH-axis activation. Sermorelin's clinical use history provides the most reassuring real-world safety context of the GHRH analogs.

Common (most users)

  1. Injection-site reactions. Redness, mild irritation, or transient pinkness at the subcutaneous injection site. The most commonly reported effect; resolved by site rotation.
  2. Transient flushing / head rush. Mild warmth or head rush shortly after injection, most common with the first few doses. Usually resolves within the first 1–2 weeks of continued dosing.
  3. Mild water retention. Reflects normal GH-mediated sodium and fluid effects. Typically mild and resolves on cycle-off.
  4. Transient appetite changes. Generally mild with Ipamorelin (selective) compared to older GHRPs that produced pronounced appetite spikes.

Less common (moderate)

  1. Numbness / tingling in hands. Mild carpal-tunnel-like sensations from GH-related fluid retention. Common with prolonged cycles; resolves on cycle-off.
  2. Mild fasting glucose elevation. GH counter-regulates insulin. Worth monitoring with fasting glucose checks during longer research cycles, particularly in pre-diabetic subjects.
  3. Headache. Typically mild and more common during dose titration. Usually resolves after the first 1–2 weeks at a given dose level.
  4. Vivid dreams or disrupted sleep onset. Reported with pre-bed dosing in some researchers. Usually adapts within the first 1–2 weeks of the cycle.

Serious (rare or theoretical)

  1. Insulin resistance with chronic use. Sustained GH-axis activation can promote insulin resistance. The primary theoretical reason for cycling — 8–12 weeks on, 4-week minimum off.
  2. Pituitary receptor desensitization. Continuous GH-axis stimulation without breaks can downregulate receptor responsiveness. Standard cycling protocols are the mitigation.
  3. Theoretical mitogenic risk. Chronic IGF-1 elevation has a theoretical tumor-stimulation concern from epidemiological associations of high baseline IGF-1 with certain cancer types. No signals have appeared in Sermorelin clinical-use data or GH secretagogue research-community use.
  4. Anti-doping prohibition. Both Sermorelin and Ipamorelin are on the WADA prohibited list (Section S2, peptide hormones / growth factors). Tested athletes should not use this stack in any form.

Sermorelin's compounding-pharmacy clinical use provides the most reassuring real-world safety data of any GHRH analog research stack component. Ipamorelin's selectivity profile means the combination avoids the cortisol elevation, prolactin elevation, and excessive appetite that older GHRP stacks produced.

Does Sermorelin + Ipamorelin interact with other drugs?

The stack has limited well-documented systemic drug interactions, but several theoretical concerns apply because GH and IGF-1 affect insulin sensitivity, fluid balance, and tissue growth. Sermorelin's clinical use history means interaction data for the GHRH-pathway component is more developed than for CJC-1295.

  1. Insulin and oral hypoglycemics. GH counter-regulates insulin. Users on insulin, metformin, or other diabetes medications may need dose adjustment. Fasting glucose is worth monitoring during cycles.
  2. Corticosteroids. Chronic corticosteroid use can suppress the GH axis at the pituitary level, potentially blunting the response to the Sermorelin component. No acute safety concern documented.
  3. Other GH-axis compounds. MK-677, HGH itself, IGF-1 LR3, CJC-1295 — overlapping mechanisms increase IGF-1 elevation without proportional benefit and amplify side effects. Avoid stacking with other GH secretagogues.
  4. Levothyroxine. GH-axis activation can shift T4-to-T3 conversion. Users on thyroid replacement medication may notice adequacy changes during GH secretagogue cycles.
  5. Component-level interactions. Cross-reference the Sermorelin and Ipamorelin individual peptide pages for full per-component interaction details.

How should Sermorelin + Ipamorelin be stored?

  1. Lyophilized (powder) form: -20°C long-term, 2–8°C short-term (refrigerated). Sermorelin is somewhat less stable than CJC-1295 at room temperature — keep refrigerated consistently.
  2. Reconstituted solution: 2–8°C, use within 30 days.
  3. Reconstitution: bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. Do not freeze the reconstituted solution. Freezing damages the peptide structure and renders it inactive.
  5. Protect from light — store in the original container or amber vial.
  6. Discard if the solution is cloudy, discolored, or contains visible particles.

What are the limitations of Sermorelin + Ipamorelin research?

Most evidence comes from preclinical models and small human studies of each component individually. The combination is widely discussed in the research community but has no controlled trial as a single product. Sermorelin's clinical-use history is the closest regulatory analog for the GHRH-pathway component.

The Sermorelin + Ipamorelin stack is NOT FDA-approved as a combination. Sermorelin has approved compounding-pharmacy use for adult GH deficiency (the GHRH-analog with the strongest regulatory history); Ipamorelin has no FDA approval. There is no controlled clinical trial of the two-peptide combination as a single product — synergy claims rest on the mechanistic GHRH+GHRP literature and each compound's individual pharmacodynamic data.

Most evidence on combination GH secretagogue stacks is mechanistic and short-term human pharmacodynamic data. Long-term effects of sustained dual-pathway GH-axis stimulation are not fully established — theoretical concerns include insulin resistance, pituitary receptor desensitization, and chronic IGF-1 elevation effects. Standard cycling (8–12 weeks on, 4-week minimum off) is the research-community mitigation strategy.

Research-grade peptide quality varies by source. Sermorelin is less stable than some GHRH analogs and more susceptible to degradation from improper storage or shipping. Third-party HPLC testing and verified cold-chain handling are strongly recommended.

Anti-doping: Both Sermorelin and Ipamorelin are on the WADA prohibited list (Section S2, peptide hormones and growth factors). Tested athletes should not use this stack in any form.

Where to source Sermorelin + Ipamorelin

Neither Sermorelin (as research-grade injectable) nor Ipamorelin is FDA-approved for over-the-counter retail sale. Both are sold by specialty research peptide vendors for laboratory use only — typically as separate vials (allowing independent dose titration) or occasionally as a pre-blended combination vial. The vendors highlighted below carry both components and have been vetted for transparent third-party testing and traceable batch documentation.

Peptide Partners10% off
Editor's Pick

Click to copy code

Shop Peptide Partners →
Spartan Peptides10% off

Carries Sermorelin and Ipamorelin

Click to copy code

Shop Spartan Peptides →
Glacier Aminos10% off
Editor's Pick

Click to copy code

Shop Glacier Aminos →

See all verified vendors →

Sermorelin + Ipamorelin FAQ

What is the Sermorelin + Ipamorelin stack?

The Sermorelin + Ipamorelin stack is a 2-component growth hormone secretagogue blend: Sermorelin (a GHRH 1-29 analog, the GHRH-pathway partner) + Ipamorelin (a selective GHS-R1a / ghrelin receptor agonist, the pulse trigger). Together they stimulate growth hormone release through two distinct pituitary receptor pathways simultaneously, producing larger and more pulsatile GH output than either compound alone. Both have short half-lives (∼10–20 min for Sermorelin, ∼2 h for Ipamorelin), preserving physiological pulsatile GH release. It's the recommended entry-point stack before stepping up to CJC-1295-based protocols.

Should I start with Sermorelin + Ipamorelin or the GH Stack?

Sermorelin + Ipamorelin is the recommended starting point. Both stacks hit the same dual-pathway mechanism (GHRH receptor + GHS-R1a), and both use short-acting components that preserve pulsatile GH release. The key distinction is regulatory footing: Sermorelin has FDA-recognized clinical history as Geref (approved for pediatric GH deficiency diagnostics; now available via compounding pharmacies for adult GH deficiency), giving it the strongest safety and regulatory pedigree of the GHRH analogs. The GH Stack (CJC-1295 no-DAC + Ipamorelin) uses CJC-1295, which has a slightly longer half-life (∼30 min vs ∼10–20 min) but no approved clinical analog. Researchers confident with GH secretagogue protocols and seeking slightly longer action per dose can step up to the GH Stack after establishing tolerability here.

What is Sermorelin's regulatory history?

Sermorelin (GHRH 1-29) was FDA-approved as Geref (sermorelin acetate) for stimulation of GH release in children with GH deficiency and as a GH-axis diagnostic tool. The branded product was withdrawn from the US market in 2002 for business reasons, not safety — it was not pulled due to safety signals. Sermorelin remains available through licensed compounding pharmacies for adult GH deficiency, making it the only GHRH analog with an approved clinical-use pathway in the US. This is why researchers position Sermorelin + Ipamorelin as the most accessible and beginner-appropriate GH secretagogue stack: the GHRH-pathway component has real-world clinical exposure data. Ipamorelin has no FDA approval and both compounds are prohibited by WADA (Section S2). Research-grade product is sold for laboratory use only.

Why is Ipamorelin the preferred GHRP partner for Sermorelin?

Ipamorelin is selective for the ghrelin / GHS-R1a receptor — it triggers GH release without meaningfully elevating cortisol, ACTH, prolactin, FSH, LH, or TSH. Older GHRPs (GHRP-2, GHRP-6, Hexarelin) produced GH release but also drove cortisol and appetite increases, which undercut the clean GH-axis profile that makes a GHRH+GHRP stack useful. Ipamorelin's selectivity means the combination avoids these side effects, producing a cleaner hormonal response.

When should I take Sermorelin + Ipamorelin?

Pre-bed dosing on an empty stomach is the standard research protocol. Growth hormone naturally pulses during slow-wave sleep, and both Sermorelin and Ipamorelin injected 30–60 minutes before bed reinforce that overnight GH pulse. An empty stomach (at least 2 hours after the last meal) is the most important timing constraint — elevated insulin and somatostatin from a recent meal will blunt the GH response. Some protocols add a second daily dose post-workout.

How does Sermorelin + Ipamorelin compare to CJC-1295 DAC + Ipamorelin?

The main differences are half-life and dosing convenience. Sermorelin has a half-life of ∼10–20 minutes; CJC-1295 no-DAC ∼30 minutes; CJC-1295 with DAC ∼6–8 days. The DAC variant (see CJC-1295 DAC + Ipamorelin) only requires 1–2 mg subcutaneously once weekly, making it convenient for researchers who prefer minimal injection frequency. The trade-off is that the long-acting DAC form produces sustained, non-pulsatile GH elevation rather than physiological pulses, and it lacks the regulatory analog that Sermorelin's clinical history provides. The Sermorelin + Ipamorelin stack is the most beginner-friendly and physiologically conservative option; CJC-1295 DAC + Ipamorelin is the most convenient once tolerability is established.

How long until results appear?

GH secretagogue stacks build effect over weeks, not days. Sleep quality improvements (deeper slow-wave sleep, better recovery) often appear within 1–2 weeks. Subjective recovery, joint, and connective-tissue changes typically emerge over 4–8 weeks. Body composition changes (lean mass support, fat distribution) accumulate over 12–24 weeks. Standard research cycles run 8–16 weeks active with a similar off-period to avoid pituitary receptor desensitization.

References

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
  2. Jørgensen JOL, et al. GHRH + GHRP Synergy: Co-Administration of GHRH Analogs with GHSR Agonists. Growth Horm IGF Res. 2001. https://pubmed.ncbi.nlm.nih.gov/11420165/
  3. Ishida J, Saitoh M, Ebner N, et al. Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development. JCSM Rapid Commun. 2020;3(1):25-37. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046879/
  5. Steiger A, Guldner J, Hemmeter U, et al. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology. 1992;56(2):211-220. https://pubmed.ncbi.nlm.nih.gov/1415528/

Published Studies

The Sermorelin + Ipamorelin combination has no controlled trial as a single product. The studies below are the key peer-reviewed sources for each component and for the dual-pathway mechanistic rationale — the empirical basis for this blend.

European Journal of Endocrinology · 1998Open Access
Ipamorelin, the First Selective Growth Hormone Secretagogue →

Raun K, Hansen BS, Johansen NL, et al.

The landmark selectivity study for Ipamorelin — the GHRP component of this stack. Established that Ipamorelin produces robust GH release with approximately 90% less cortisol elevation and no meaningful ACTH or prolactin response compared to older GHRPs (GHRP-2, GHRP-6, Hexarelin). This clean hormonal profile is exactly why Ipamorelin was selected as the GHS-R1a partner for both Sermorelin and CJC-1295 stacks — it adds GH pulse triggering through the ghrelin receptor without the cortisol and appetite side effects of earlier GHRPs.

Growth Hormone & IGF Research · 2001Paywalled
GHRH + GHRP Synergy: Co-Administration of GHRH Analogs with GHSR Agonists →

Jørgensen JOL, et al.

Mechanistic study demonstrating supra-additive GH release when GHRH analogs and GHSR (ghrelin receptor) agonists are co-administered — the scientific foundation for the Sermorelin + Ipamorelin stack's design. Co-administration produced 2–4× greater GH area under the curve compared to either compound alone. The cAMP pathway (Sermorelin / GHRHR) and the calcium/PKC pathway (Ipamorelin / GHS-R1a) converge at the somatotroph, where simultaneous activation amplifies the secretory response beyond what either signal produces alone.

JCSM Rapid Communications · 2020Open Access
Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development →

Ishida J, Saitoh M, Ebner N, et al.

A comprehensive review of the GH secretagogue class providing clinical context for the Sermorelin + Ipamorelin combination. Covers the evolution from native GHRH to stable analogs like Sermorelin (GHRH 1-29), documenting how the dual-pathway approach became the preferred research protocol for GH axis optimization. Also addresses why secretagogue stacks are considered preferable to direct HGH — stimulating endogenous production preserves natural feedback mechanisms and avoids supraphysiological IGF-1 spikes.

Clinical Interventions in Aging · 2006Open Access
Sermorelin: A Synthetic Analog of Growth Hormone–Releasing Factor →

Walker RF

A clinical review of Sermorelin's mechanism, pharmacology, and historical use as Geref. Documents Sermorelin's FDA-recognized clinical history for GH deficiency diagnostics and pediatric GH deficiency treatment, and its availability through compounding pharmacies for adult use — the regulatory foundation for positioning it as the most accessible GHRH analog. The paper establishes the short half-life (~10–20 minutes), dose-dependent GH stimulation, and the preservation of pituitary feedback regulation that distinguishes Sermorelin from longer-acting GHRH analogs.

American Journal of Physiology · 1992Paywalled
Effects of Growth Hormone-Releasing Hormone on Sleep and Brain Activity in Humans →

Steiger A, Guldner J, Hemmeter U, et al.

Human study establishing the connection between GHRH administration and enhanced slow-wave sleep — the mechanistic basis for pre-bed dosing of GHRH analogs like Sermorelin. GHRH administration increased slow-wave sleep duration and reinforced the natural nocturnal GH pulse. This study underpins the pre-bed dosing protocol used across all GHRH analog research stacks: timing the injection to synchronize with the body's sleep-onset GH surge produces the largest amplitude GH pulse and drives the sleep-quality improvements that are among the earliest subjective effects reported by researchers.

GH AxisGrowth Hormone SecretagogueRecoveryCombination BlendBeginner-Friendly

Related Peptides

SermorelinIpamorelinCJC-1295MK-677

Related Blends

GH Stack (CJC-1295 + Ipamorelin)CJC-1295 DAC + Ipamorelin

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

We may earn commissions from peptide vendor affiliate links.

Have a question about Sermorelin + Ipamorelin? Send us an email →

For educational and research purposes only. Not medical advice. Not for human use.